Check out the full NCCN guidelines by creating a FREE account at www.nccn.org
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic – Released September 7th, 2022
› Testing eligibility based on personal history of any type of breast cancer in females was updated from age ≤45 to ≤50 making more females with breast cancer eligible for testing regardless of family history or type of breast cancer.
› BRCA1/2: Removed ovarian cancer screening consideration from care guidelines given the lack of evidence to support that screening is useful to reliably detect ovarian cancer early.
› BRCA1/2: Clarified that hormone replacement therapy (HRT) is a consideration in pre-menopausal patients without breast cancer or other contraindications for HRT. Perioperative menopause management consultation was also included as a consideration.
› CHEK2/ATM: Age to start breast MRI screening in females was reduced from age 40 to 30-35 making more females eligible for screening at an earlier age.
› PALB2: Added consideration of risk-reducing salpingo-oophorectomy at age >45.
› Added a table at the end of the guidelines (see page 54 on the SUMM-1 page) to summarize inherited cancer content across all NCCN guidelines, including live links to the guidelines and sections referenced.
Genetic/Familial High-Risk Assessment: Colorectal – Released June 8th, 2022
› Testing criteria was expanded to offer germline multi-gene panel testing to all individuals diagnosed with colorectal cancer below age 50; and to consider testing for all others, particularly those with a family history or evidence of mismatch repair deficiency (but not restricted to just these patients).
1Hu et al. N Engl J Med. 2021;384(5):440-451. PMID: 33471974;
2Kotsopoulos et al. Cancer Epidemiol Biomarkers Prev. 2022;31(7):1351-1358. PMID: 35477169.
Social media post September 25th, 2022. Available at: https://tinyurl.com/post9252022.